Shire recalls some Daytrana shipments

Mom, I can't get my ADHD patch on! Shire is recalling some lots of Daytrana, its attention deficit hyperactivity disorder patch--not because of safety issues, but because patients are having a hard time removing the release liner so they can administer the drug. The withdrawal is expected to cost the British drug maker some $10 million.

- see this release
- here's the report from MarketWatch

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.